Published in Medical Letter on the CDC and FDA, August 29th, 2004
Maker Eli Lilly & Co. is banking on Cymbalta as a successor to its once-blockbuster Prozac. Cymbalta, known chemically as duloxetine, is one of a newer class of antidepressants that targets two brain chemicals involved in depression, serotonin and norepinephrine.
It's the first antidepressant to hit the market since the Food and Drug Administration (FDA) began investigating whether such drugs can sometimes increase the risk of suicide, particularly when used by teenagers, or if patients' underlying depression is to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA